Done sou Salè H1B

Akèy › Anplwayè › Boehringer Ingelheim Pharmaceuticals, Inc. › Senior Clinical Data Scientist

Senior Clinical Data Scientist nan Boehringer Ingelheim Pharmaceuticals, Inc.: Salè H-1B

21 aplikasyon kondisyon travay pou tit travay Senior Clinical Data Scientist nan Boehringer Ingelheim Pharmaceuticals, Inc.. Salè baz medyàn ofri $142,314; mwatye mitan $137,405–$150,000.

Demann (LCA)21
Salè medyan ofri$142,314
Mwatye salè yo$137,405–$150,000
10yèm–90yèm pousantaj$131,533–$157,590

Pa ane fiskal

Ane fiskalLCASalè medyan
FY20238$137,294
FY20243$150,000
FY20255$141,990
FY20265$145,800

Aplikasyon

Salè bazKoteSoumètDat kòmansmanEstati
$145,370
Nivo III		Ridgefield, CTMay 27, 2026Oct 1, 2026Certifye
$141,776
Nivo III		Ridgefield, CTMay 7, 2026May 18, 2026Certifye
$145,800
Nivo III		Ridgefield, CTMar 20, 2026Aug 1, 2026Certifye
$157,590
Nivo III		Ridgefield, CTJan 23, 2026May 15, 2026Certifye
$158,216
Nivo III		Ridgefield, CTNov 25, 2025Feb 12, 2026Certifye
$155,920
Nivo III		Ridgefield, CTAug 7, 2025Dec 1, 2025Certifye
$142,179
Nivo II		Ridgefield, CTMar 10, 2025Aug 20, 2025Certifye
$137,405
Nivo II		Ridgefield, CTMar 6, 2025Aug 24, 2025Certifye
$141,990
Nivo II		Ridgefield, CTFeb 5, 2025Aug 3, 2025Certifye
$137,511
Nivo II		Ridgefield, CTJan 9, 2025Jan 13, 2025Certifye
$160,000
Nivo IV		Ridgefield, CTApr 25, 2024May 6, 2024Certifye
$150,000
Nivo IV		Ridgefield, CTMar 21, 2024Apr 8, 2024Certifye
$132,600
Nivo III		Ridgefield, CTMar 14, 2024Aug 25, 2024Certifye
$155,000
Nivo IV		Ridgefield, CTSep 22, 2023Oct 23, 2023Certifye
$145,000
Nivo IV		Ridgefield, CTJul 30, 2023Aug 21, 2023Certifye
$132,275
Nivo III		Ridgefield, CTJun 15, 2023Jun 26, 2023Certifye
$124,619–$150,000
Nivo III		Ridgefield, CTMay 24, 2023Oct 1, 2023Certifye
$150,000
Nivo III		Ridgefield, CTMay 1, 2023May 15, 2023Certifye
$124,619–$150,000
Nivo III		Ridgefield, CTMar 10, 2023Aug 1, 2023Certifye
$142,314–$150,000
Nivo III		Ridgefield, CTMar 9, 2023Aug 1, 2023Certifye
$131,533
Nivo III		Ridgefield, CTNov 15, 2022Dec 1, 2022Certifye

Lòt travay nan Boehringer Ingelheim Pharmaceuticals, Inc.

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).